Acasti Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acasti Pharma generated cash of -$19,997,000, which is more than the previous year. Cash used in financing activities reached the amount of $72,271,000 last year. Net change in cash is therefore $46,532,000.
Cash Flow
| 2017 | -11.91M | -1.29M | 58.89M |
|---|---|---|---|
| 2018 | -14.99M | -2.15M | 6.87M |
| 2019 | -41.73M | -1.99M | 109.75M |
| 2020 | -39.33M | -2.37M | 73.42M |
| 2021 | -66.01M | -12.58M | -235K |
| 2022 | -19.99M | -5.01M | 72.27M |
ACST.V Cash Flow Statement (2017 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 66.91M | 143.17M | 113.57M | 48.58M | 61.36M | 13.18M |
Operating activities | ||||||
Net income | -64.91M | -75.66M | -44.08M | -43.03M | -16.23M | -12.72M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 3.60M | 4.64M | 4.15M | 3.06M | 640K | 398K |
Stock-based compensation expense | 5.04M | 7.64M | 8.65M | 5.56M | 867K | 770K |
| Deferred income tax benefit | 5.04M | 7.64M | 8.65M | 5.56M | 867K | 770K |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -341K | -1.94M | -3.57M | -3.61M | -4.99M | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -19.99M | -66.01M | -39.33M | -41.73M | -14.99M | -11.91M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -5.01M | -12.58M | -2.37M | -1.99M | -2.15M | -1.29M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5.01M | -12.58M | -2.37M | -1.99M | -2.15M | -1.29M |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -438K | -1.41M | 0 | 0 | 0 |
Cash used in financing activities | 72.27M | -235K | 73.42M | 109.75M | 6.87M | 58.89M |
Net Change In Cash | 46.53M | -76.26M | 29.60M | 64.99M | -12.78M | 48.17M |
Cash at end of period | 113.44M | 66.91M | 143.17M | 113.57M | 48.58M | 61.36M |